Paper Details

  1. Home
  2. Paper Details

Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.

Author: BarrEliav, Ben AriZiv, BrownDeborah D, ButtertonJoan R, DiNubileMark J, GhalibReem, NguyenBach-Yen, PockrosPaul J, ReddyK Rajender, RobertsonMichael N, WahlJanice, WanShuyan, ZeuzemStefan, ZhaoYue

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A randomized, blinded, placebo-controlled trial found that grazoprevir-elbasvir achieved high sustained virological response (SVR12) rates in treatment-naive patients with genotype 1, 4, or 6 hepatitis C virus (HCV) infection. This once-daily, all-oral, fixed-combination regimen is a promising new therapeutic option for chronic HCV infection.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Novel interferon- and ribavirin-free regimens are needed to treat hepatitis C virus (HCV) infection. OBJECTIVE: To evaluate the safety and efficacy of grazoprevir (NS3/4A protease inhibitor) and elbasvir (NS5A inhibitor) in treatment-naive patients. DESIGN: Randomized, blinded, placebo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.7326/M15-0785

データ提供：米国国立医学図書館（NLM）

Grazoprevir-Elbasvir: A Powerful Oasis in the Desert of Hepatitis C

This study dives into the exciting field of [hepatitis C treatment], exploring the potential of a new combination therapy, [grazoprevir-elbasvir], for [treatment-naive patients] with [chronic hepatitis C virus (HCV) genotype 1, 4, or 6 infection]. Think of this like a journey through a desert, where [grazoprevir-elbasvir] can provide a powerful oasis of hope for those struggling with [HCV infection]. This research investigates the safety and efficacy of this regimen in [cirrhotic and noncirrhotic patients], analyzing the proportion of patients achieving [sustained virologic response 12 weeks after treatment (SVR12)].

Grazoprevir-Elbasvir: A Beacon of Hope in the Desert

The authors found that [grazoprevir-elbasvir] achieved high [SVR12 rates] in both [cirrhotic and noncirrhotic patients] with [HCV genotype 1, 4, or 6 infection], demonstrating its potential as a powerful and effective treatment option. Their findings also suggest that this regimen is generally well tolerated, with a low incidence of serious adverse events.

A New Oasis in the Desert of HCV Treatment: Grazoprevir-Elbasvir

This research provides exciting news for patients with [chronic HCV infection], offering a promising new treatment option that is both effective and well tolerated. The study highlights the need for further research into the long-term effects of this regimen and its potential for treating different genotypes of HCV infection.

Dr.Camel's Conclusion

This study provides strong evidence that grazoprevir-elbasvir is a highly effective and well-tolerated treatment for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection. The regimen's high SVR12 rates and favorable safety profile make it a promising new therapeutic option for patients seeking a cure for HCV infection.

Date :
  1. Date Completed 2015-09-21
  2. Date Revised 2022-09-09
Further Info :

Pubmed ID

25909356

DOI: Digital Object Identifier

10.7326/M15-0785

Related Literature

Article Analysis
・Effective treatment of hepatitis c
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.